TEM vs RXRX
TEM and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RXRXRecursion Pharmaceuticals, Inc. |
|---|---|---|
| Market cap | $14.13M | $2.05B |
| P/B | 0.03 | — |
| P/S | 0.0x | 28.6x |
| Revenue | $1.51B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 26.9% |
| Net income | -$189.27M(TTM) | — |
| Earnings growth (YoY) | 65.3% | -39.1% |
| EPS, diluted | $-1.06(TTM) | — |
| EBIT margin | -19.9% | -867.9% |
| ROE | -49.0% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | -12.0% | -27.5% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: TEM frente a RXRX
| Métrica | TEM | RXRX |
|---|---|---|
| Valor final | $19.5K | $4.1K |
| Retorno total | +95.0% | -58.6% |
| CAGR | +32.3% | -30.9% |
| Volatilidad | 97.1% | 84.4% |
| Sharpe | 0.72 | -0.08 |
| Sortino | 1.15 | -0.12 |
| Caída máxima | -59.8% | -73.9% |
Basado en 598 días de negociación comunes, 2024-06-14 → 2026-11-02 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)